Trials
3 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ulcerative Colitis (2 trials), Inflammatory Bowel Diseases (2 trials), Colitis (2 trials), Colitis, Ulcerative (2 trials)
- Main trialPhase 2
- “This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.”In the company’s words, NCT07012395 on ClinicalTrials.gov
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up2
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 2 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jun 2027 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | |
| Phase 2Enrolling by invitation | 2 Mar 2029 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | |
| Phase 1Active, not recruiting | 18 Nov 2026 | A Study of SPY003-207 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026